Literature DB >> 8682138

The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group.

K M Fox1, D Mulcahy, I Findlay, I Ford, H J Dargie.   

Abstract

OBJECTIVES: To determine the effects of atenolol, nifedipine and their combination on exercise parameters and ambulatory ischaemic activity in patients with mild chronic stable angina.
SETTING: Multicentre, multinational study involving 608 patients from 69 centres in nine countries.
DESIGN: Placebo washout followed by double-blind parallel-group study comparing atenolol 50 mg bd, nifedipine SR 20 mg bd, and their combination. Patients underwent maximal exercise testing using either a bicycle (n = 289) or treadmill (n = 319) and 48 h of ambulatory ST segment monitoring outside the hospital environment at the end of the placebo washout period and after 6 weeks of active therapy.
RESULTS: Both medications alone and in combination caused significant improvements in exercise parameters and significant reductions in ischaemic activity during daily activities, when compared with placebo. There were, however, no significant differences between groups, for any of the measured ischaemic parameters although combination therapy resulted in a greater fall in resting systolic and diastolic blood pressure than either treatment alone.
CONCLUSIONS: In the management of mild chronic stable angina there appears to be little advantage gained from using combination therapy for ischaemia reduction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8682138     DOI: 10.1093/oxfordjournals.eurheartj.a014699

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  25 in total

Review 1.  Heart medications: indications and interactions in stress testing.

Authors:  B H Duncan; L E Sillaman
Journal:  J Nucl Cardiol       Date:  1999 May-Jun       Impact factor: 5.952

Review 2.  Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.

Authors:  William C Stanley; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2005-12       Impact factor: 4.214

Review 3.  Metabolic therapy for heart disease: impact of trimetazidine.

Authors:  Hani N Sabbah; William C Stanley
Journal:  Heart Fail Rev       Date:  2005-12       Impact factor: 4.214

4.  1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart?

Authors:  F H Leenen
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

5.  Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue?

Authors:  Stephane Noble; Marco Roffi
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

6.  Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).

Authors:  P Hjemdahl; S V Eriksson; C Held; L Forslund; P Näsman; N Rehnqvist
Journal:  Heart       Date:  2005-06-10       Impact factor: 5.994

Review 7.  Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.

Authors:  K J McClellan; G L Plosker
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

8.  Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).

Authors:  J A Van Der Vring; M C Daniëls; N J Holwerda; P J Withagen; A Schelling; T J Cleophas; M G Hendriks
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

Review 9.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

10.  Ivabradine: the evidence of its therapeutic impact in angina.

Authors:  Guillaume Marquis-Gravel; Jean-Claude Tardif
Journal:  Core Evid       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.